Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
Tóm tắt
The use of ustekinumab in pediatric patients with inflammatory bowel disease (IBD) is off-label and the data are limited. We conducted a systematic review evaluating the efficacy and safety of ustekinumab in pediatric IBD. We systematically searched PubMed, EMBASE and Cochrane databases for studies of ustekinumab in children and adolescents with IBD investigating clinical remission, clinical response, corticosteroid-free (CS-free) remission, endoscopic remission/response, or safety up to March 17, 2023. A random-effects model was used for calculating summary estimates. Eleven studies, comprising 370 patients were included. For Crohn’s disease (CD), the pooled clinical remission rates were 34% (73/204) at 8–16 weeks and 46% (60/129) at 1 year. The pooled CS-free clinical remission rates were 23% (10/44) at 8–16 weeks and 45% (42/96) at 1 year. For ulcerative colitis (UC)/IBD unspecified (IBD-U), the pooled CS-free clinical remission rates were 24% (6/25) at 26 weeks and 46% (16/35) at 1 year. Endoscopic remission was found in 0–37.5% of CD and 63.6% of UC. Serious adverse events were reported in 3.5% of patients. About one half of patients required reduction in dose intervals and 62.75% patients could continue ustekinumab therapy at 1 year or final visit. According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.
Tài liệu tham khảo
Jakobsen C, Bartek J Jr, Wewer V, Vind I, Munkholm P, Groen R, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease—a population-based study. Aliment Pharmacol Ther. 2011;34(10):1217–24.
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–95.
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1): e135.
Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182–97.
Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61(6):918–32.
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–41.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–60.
https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html
https://www.drugs.com/newdrugs/janssen-announces-fda-approval-stelara-ustekinumab-adults-moderately-severely-active-ulcerative-5084.html
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17.
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohn’s Colitis. 2020;2:2.
Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, et al. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020;69(1):32–41.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.
Guo B, Moga C, Harstall C, Schopflocher D. A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol. 2016;69:199-207.e2.
Moga C, Guo B, Schopflocher D, Harstall C. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton AB: Institute of Health Economics, (2012).
Chavannes M, Martinez-Vinson C, Hart L, Kaniki N, Chao CY, Lawrence S, et al. Management of paediatric patients with medically refractory crohn’s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13(5):578–84.
Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7.
Takeuchi I, Arai K, Kyodo R, Sato T, Tokita K, Hirano Y, et al. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children’s hospital in Japan. J Gastroenterol Hepatol. 2021;36(1):125–30.
Dhaliwal J, McKay HE, Deslandres C, Debruyn J, Wine E, Wu A, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. Aliment Pharmacol Ther. 2021;53(12):1300–8.
Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(8):1210–4.
Kim FS, Patel PV, Stekol E, Ali S, Hamandi H, Heyman MB, et al. Experience using ustekinumab in pediatric patients with medically refractory crohn disease. J Pediatr Gastroenterol Nutr. 2021;73(5):610–4.
Do P, Andersen J, Patel A, Semrin G, Sifuentes-Dominguez L, Luu P, et al. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review. F1000Research. 2020;9:316.
Cohen A, Ahmed N, Sant’Anna A. Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience. Intestinal Res. 2021;19(2):217–24.
Rosh JR, Turner D, Griffiths A, Cohen SA, Jacobstein D, Adedokun OJ, et al. Ustekinumab in paediatric patients with moderately to severely active crohn’s disease: pharmacokinetics, safety, and efficacy results from unistar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931–42.
Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, Kolho KL, Levine A, Olbjørn C, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric crohn disease (the Speed-up Study): a multicenter study from the pediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717–23.
Koudsi M, Martinez-Vinson C, Pigneur B, Willot S, Djamal D, Enaud R, et al. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID. J Pediatr Gastroenterol Nutr. 2023;2:2.
Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, et al. Re-induction with intravenous ustekinumab in patients with crohn’s disease and a loss of response to this therapy. Inflamm Bowel Dis. 2022;28(1):41–7.
Iborra M, Beltrán B, Fernández-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, et al. Real-world long-term effectiveness of ustekinumab in Crohn’s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52(6):1017–30.
Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, et al. Ustekinumab is associated with real-world long-term effectiveness and improved health-related quality of life in crohn’s disease. Dig Dis Sci. 2023;68(1):65–76.
Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, Arbonés-Mainar JM, Caballol B, Gisbert JP, et al. Effectiveness and safety of ustekinumab in elderly patients with crohn’s disease: real world evidence from the ENEIDA registry. J Crohns Colitis. 2023;17(1):83–91.
Taxonera C, Olivares D, López-García ON, Alba C. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–9.
Rubín de Célix C, Chaparro M, Gisbert JP. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of crohn's disease: systematic review and meta-analysis of observational studies. J Clin Med. 2022;11:14
Yang H, Li B, Guo Q, Tang J, Peng B, Ding N, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;55(7):764–77.
Casas Deza D, García López S, Lafuente Blasco M, Vicente Lidón R, Nerín de la Puerta J, Peña Gonzalez E, et al. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort. Gastroenterologia y hepatologia. 2020;43(3):126-32.
Parra RS, Chebli JMF, Queiroz NSF, Damião A, de Azevedo MFC, Chebli LA, et al. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study. BMC Gastroenterol. 2022;22(1):199.
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232–43.
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833–9.
Kubesch A, Rueter L, Farrag K, Krause T, Stienecker K, Hausmann J, et al. Short and Long-term effectiveness of ustekinumab in patients with crohn’s disease: real-world data from a German IBD cohort. J Clin Med. 2019;8:12.